Two distinct subtypes of hepatitis B virus–related acute liver failure are separable by quantitative serum immunoglobulin M anti‐hepatitis B core antibody and hepatitis B virus DNA levels
dc.contributor.author | Dao, Doan Y. | en_US |
dc.contributor.author | Hynan, Linda S. | en_US |
dc.contributor.author | Yuan, He‐jun | en_US |
dc.contributor.author | Sanders, Corron | en_US |
dc.contributor.author | Balko, Jody | en_US |
dc.contributor.author | Attar, Nahid | en_US |
dc.contributor.author | Lok, Anna Suk-Fong | en_US |
dc.contributor.author | Word, R. Ann | en_US |
dc.contributor.author | Lee, William M. | en_US |
dc.date.accessioned | 2012-03-16T15:55:32Z | |
dc.date.available | 2013-05-01T17:24:42Z | en_US |
dc.date.issued | 2012-03 | en_US |
dc.identifier.citation | Dao, Doan Y.; Hynan, Linda S.; Yuan, He‐jun ; Sanders, Corron; Balko, Jody; Attar, Nahid; Lok, Anna S.F.; Word, R. Ann; Lee, William M. (2012). "Two distinct subtypes of hepatitis B virusâ related acute liver failure are separable by quantitative serum immunoglobulin M antiâ hepatitis B core antibody and hepatitis B virus DNA levels ." Hepatology 55(3): 676-684. <http://hdl.handle.net/2027.42/90152> | en_US |
dc.identifier.issn | 0270-9139 | en_US |
dc.identifier.issn | 1527-3350 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/90152 | |
dc.description.abstract | Hepatitis B virus (HBV)‐related acute liver failure (HBV‐ALF) may occur after acute HBV infection (AHBV‐ALF) or during an exacerbation of chronic HBV infection (CHBV‐ALF). Clinical differentiation of the two is often difficult if a previous history of HBV is not available. Quantitative measurements of immunoglobulin M (IgM) anti–hepatitis B core antibody (anti‐HBc) titers and of HBV viral loads (VLs) might allow the separation of AHBV‐ALF from CHBV‐ALF. Of 1,602 patients with ALF, 60 met clinical criteria for AHBV‐ALF and 27 for CHBV‐ALF. Sera were available on 47 and 23 patients, respectively. A quantitative immunoassay was used to determine IgM anti‐HBc levels, and real‐time polymerase chain reaction (rtPCR) was used to determine HBV VLs. AHBV‐ALFs had much higher IgM anti‐HBc titers than CHBV‐ALFs (signal‐to‐noise [S/N] ratio median: 88.5; range, 0‐1,120 versus 1.3, 0‐750; P < 0.001); a cut point for a S/N ratio of 5.0 correctly identified 44 of 46 (96%) AHBV‐ALFs and 16 of 23 (70%) CHBV‐ALFs; the area under the receiver operator characteristic curve was 0.86 ( P < 0.001). AHBV‐ALF median admission VL was 3.9 (0‐8.1) log10 IU/mL versus 5.2 (2.0‐8.7) log10 IU/mL for CHBV‐ALF ( P < 0.025). Twenty percent (12 of 60) of the AHBV‐ALF group had no hepatitis B surface antigen (HBsAg) detectable on admission to study, wheras no CHBV‐ALF patients experienced HBsAg clearance. Rates of transplant‐free survival were 33% (20 of 60) for AHBV‐ALF versus 11% (3 of 27) for CHBV‐ALF ( P = 0.030). Conclusions: AHBV‐ALF and CHBV‐ALF differ markedly in IgM anti‐HBc titers, in HBV VLs, and in prognosis, suggesting that the two forms are, indeed, different entities that might each have a unique pathogenesis. (H EPATOLOGY 2011) | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.title | Two distinct subtypes of hepatitis B virus–related acute liver failure are separable by quantitative serum immunoglobulin M anti‐hepatitis B core antibody and hepatitis B virus DNA levels | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI | en_US |
dc.contributor.affiliationother | Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390‐8887 | en_US |
dc.contributor.affiliationother | Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX | en_US |
dc.contributor.affiliationother | Department of Clinical Sciences and Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX | en_US |
dc.contributor.affiliationother | Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX | en_US |
dc.identifier.pmid | 21987355 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/90152/1/24732_ftp.pdf | |
dc.identifier.doi | 10.1002/hep.24732 | en_US |
dc.identifier.source | Hepatology | en_US |
dc.identifier.citedreference | Garson JA, Grant PR, Ayliffe U, Ferns RB, Tedder RS. Real‐time PCR quantitation of hepatitis B virus DNA using automated sample preparation and murine cytomegalovirus internal control. J Virol Methods 2005; 126: 207 ‐ 213. | en_US |
dc.identifier.citedreference | Inoue K, Yoshiba M, Sekiyama K, Okamoto H, Mayumi M. Clinical and molecular virological differences between fulminant hepatic failures following acute and chronic infection with hepatitis B virus. J Med Virol 1998; 55: 35 ‐ 41. | en_US |
dc.identifier.citedreference | Umemura T, Tanaka E, Kiyosawa K, Kumada H. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 2008; 47: e52 ‐ e56. | en_US |
dc.identifier.citedreference | Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056 ‐ 1075. | en_US |
dc.identifier.citedreference | Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733 ‐ 1745. | en_US |
dc.identifier.citedreference | Krogsgaard K, Kryger P, Aldershvile J, Andersson P, Brechot C. Hepatitis B virus DNA in serum from patients with acute hepatitis B. Hepatology 1985; 5: 10 ‐ 13. | en_US |
dc.identifier.citedreference | Trepo CG, Robert D, Motin J, Trepo D, Sepetjian M, Prince AM. Hepatitis B antigen (HBsAg) and/or antibodies (anti‐HBs and anti‐HBc) in fulminant hepatitis: pathogenic and prognostic significance. Gut 1976; 17: 10 ‐ 13. | en_US |
dc.identifier.citedreference | Woolf IL, El Sheikh N, Cullens H, Lee WM, Eddleston AL, Williams R, Zuckerman AJ. Enhanced HBsAb production in pathogenesis of fulminant viral hepatitis type B. Br Med J 1976; 2: 669 ‐ 671. | en_US |
dc.identifier.citedreference | Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49: S156 ‐ S165. | en_US |
dc.identifier.citedreference | Shimizu M, Ohyama M, Takahashi Y, Udo K, Kojima M, Kametani M, et al. Immunoglobulin M antibody against hepatitis B core antigen for the diagnosis of fulminant type B hepatitis. Gastroenterology 1983; 84: 604 ‐ 610. | en_US |
dc.identifier.citedreference | Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 1009 ‐ 1022. | en_US |
dc.identifier.citedreference | Colloredo G, Bellati G, Leandro G, Colombatto P, Rho A, Bissoli F, et al. Quantitative analysis of IgM anti‐HBc in chronic hepatitis B patients using a new “gray‐zone” for the evaluation of borderline” values. J Hepatol 1996; 25: 644 ‐ 648. | en_US |
dc.identifier.citedreference | Lee WM. Acute liver failure. N Engl J Med 1993; 329: 1862 ‐ 1872. | en_US |
dc.identifier.citedreference | Sjogren M, Hoofnagle JH. Immunoglobulin M antibody to hepatitis B core antigen in patients with chronic type B hepatitis. Gastroenterology 1985; 89: 252 ‐ 258. | en_US |
dc.identifier.citedreference | Fink K, Manjarrez‐Orduno N, Schildknecht A, Weber J, Senn BM, Zinkernagel RM, Hengartner H. B cell activation state‐governed formation of germinal centers following viral infection. J Immunol 2007; 179: 5877 ‐ 5885. | en_US |
dc.identifier.citedreference | Huang YW, Lin CL, Chen PJ, Lai MY, Kao JH, Chen DS. Higher cut‐off index value of immunoglobulin M antibody to hepatitis B core antigen in Taiwanese patients with hepatitis B. J Gastroenterol Hepatol 2006; 21: 859 ‐ 862. | en_US |
dc.identifier.citedreference | Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554 ‐ 559. | en_US |
dc.identifier.citedreference | Yuen MF, Sablon E, Wong DK, Yuan HJ, Wong BC, Chan AO, Lai CL. Role of hepatitis B virus genotypes in chronic hepatitis B exacerbation. Clin Infect Dis 2003; 37: 593 ‐ 597. | en_US |
dc.identifier.citedreference | Ozasa A, Tanaka Y, Orito E, Sugiyama M, Kang JH, Hige S, et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 2006; 44: 326 ‐ 334. | en_US |
dc.identifier.citedreference | Okamoto H, Yotsumoto S, Akahane Y, Yamanaka T, Miyazaki Y, Sugai Y, et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990; 64: 1298 ‐ 1303. | en_US |
dc.identifier.citedreference | Liang TJ, Hasegawa K, Munoz SJ, Shapiro CN, Yoffe B, McMahon BJ, et al. Hepatitis B virus precore mutation and fulminant hepatitis in the United States. A polymerase chain reaction‐based assay for the detection of specific mutation. J Clin Invest 1994; 93: 550 ‐ 555. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.